Literature DB >> 34347570

Novel malaria vaccines.

Matthew B Laurens1.   

Abstract

Malaria vaccines hold significant promise for life-saving benefit, especially to children who bear the major burden of malaria mortality. The RTS,S/AS01 malaria vaccine provides moderate efficacy and is being tested in implementation studies. In parallel, multiple strategies are being advanced to test next-generation malaria vaccines, including novel approaches that build on principles learned from RTS,S development, vaccination with radiation-attenuated sporozoites, and development of monoclonal antibodies targeting immunogenic peptides. Novel vaccine delivery approaches are also being advanced, including self-amplifying RNA vaccine delivery, self-assembling protein nanoparticle methods, circumsporozoite protein-based approaches, and whole organism vaccination. Techniques employed for COVID-19 vaccine development should also be considered for malaria vaccination, including sustained release polymer nanoparticle hydrogel vaccination and charge-altering releasable transporters. As vaccine science advances and new approaches optimize knowledge gained, highly effective malaria vaccines that provide sustained protection are within reach.

Entities:  

Keywords:  Plasmodium falciparum; malaria elimination; malaria vaccine

Mesh:

Substances:

Year:  2021        PMID: 34347570      PMCID: PMC8827625          DOI: 10.1080/21645515.2021.1947762

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  25 in total

1.  Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.

Authors:  Mahamadou S Sissoko; Sara A Healy; Abdoulaye Katile; Freda Omaswa; Irfan Zaidi; Erin E Gabriel; Bourama Kamate; Yacouba Samake; Merepen A Guindo; Amagana Dolo; Amadou Niangaly; Karamoko Niaré; Amatigue Zeguime; Kourane Sissoko; Hama Diallo; Ismaila Thera; Kelly Ding; Michael P Fay; Elise M O'Connell; Thomas B Nutman; Sharon Wong-Madden; Tooba Murshedkar; Adam J Ruben; Minglin Li; Yonas Abebe; Anita Manoj; Anusha Gunasekera; Sumana Chakravarty; B Kim Lee Sim; Peter F Billingsley; Eric R James; Michael Walther; Thomas L Richie; Stephen L Hoffman; Ogobara Doumbo; Patrick E Duffy
Journal:  Lancet Infect Dis       Date:  2017-02-16       Impact factor: 25.071

2.  Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.

Authors:  Labdhi Seth; Karen M Bingham Ferlez; Stephen A Kaba; Derek M Musser; Sharareh Emadi; Gary R Matyas; Zoltan Beck; Carl R Alving; Peter Burkhard; David E Lanar
Journal:  Vaccine       Date:  2017-03-06       Impact factor: 3.641

3.  Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.

Authors:  Robert A Seder; Lee-Jah Chang; Mary E Enama; Kathryn L Zephir; Uzma N Sarwar; Ingelise J Gordon; LaSonji A Holman; Eric R James; Peter F Billingsley; Anusha Gunasekera; Adam Richman; Sumana Chakravarty; Anita Manoj; Soundarapandian Velmurugan; MingLin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Floreliz H Mendoza; Jamie G Saunders; Martha C Nason; Jason H Richardson; Jittawadee Murphy; Silas A Davidson; Thomas L Richie; Martha Sedegah; Awalludin Sutamihardja; Gary A Fahle; Kirsten E Lyke; Matthew B Laurens; Mario Roederer; Kavita Tewari; Judith E Epstein; B Kim Lee Sim; Julie E Ledgerwood; Barney S Graham; Stephen L Hoffman
Journal:  Science       Date:  2013-08-08       Impact factor: 47.728

4.  Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Authors:  Jason A Regules; Susan B Cicatelli; Jason W Bennett; Kristopher M Paolino; Patrick S Twomey; James E Moon; April K Kathcart; Kevin D Hauns; Jack L Komisar; Aziz N Qabar; Silas A Davidson; Sheetij Dutta; Matthew E Griffith; Charles D Magee; Mariusz Wojnarski; Jeffrey R Livezey; Adrian T Kress; Paige E Waterman; Erik Jongert; Ulrike Wille-Reece; Wayne Volkmuth; Daniel Emerling; William H Robinson; Marc Lievens; Danielle Morelle; Cynthia K Lee; Bebi Yassin-Rajkumar; Richard Weltzin; Joe Cohen; Robert M Paris; Norman C Waters; Ashley J Birkett; David C Kaslow; W Ripley Ballou; Christian F Ockenhouse; Johan Vekemans
Journal:  J Infect Dis       Date:  2016-06-13       Impact factor: 5.226

5.  Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Authors:  Mehreen S Datoo; Magloire H Natama; Athanase Somé; Ousmane Traoré; Toussaint Rouamba; Duncan Bellamy; Prisca Yameogo; Daniel Valia; Moubarak Tegneri; Florence Ouedraogo; Rachidatou Soma; Seydou Sawadogo; Faizatou Sorgho; Karim Derra; Eli Rouamba; Benedict Orindi; Fernando Ramos Lopez; Amy Flaxman; Federica Cappuccini; Reshma Kailath; Sean Elias; Ekta Mukhopadhyay; Andres Noe; Matthew Cairns; Alison Lawrie; Rachel Roberts; Innocent Valéa; Hermann Sorgho; Nicola Williams; Gregory Glenn; Louis Fries; Jenny Reimer; Katie J Ewer; Umesh Shaligram; Adrian V S Hill; Halidou Tinto
Journal:  Lancet       Date:  2021-05-05       Impact factor: 202.731

6.  Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.

Authors:  Katharine A Collins; Rebecca Snaith; Matthew G Cottingham; Sarah C Gilbert; Adrian V S Hill
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

7.  Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen.

Authors:  Nicole G Bender; Prachi Khare; Juan Martinez; Rebecca E Tweedell; Vincent O Nyasembe; Borja López-Gutiérrez; Abhai Tripathi; Dustin Miller; Timothy Hamerly; Eric M Vela; Ryan R Davis; Randall F Howard; Sandrine Nsango; Ronald R Cobb; Matthias Harbers; Rhoel R Dinglasan
Journal:  NPJ Vaccines       Date:  2021-04-06       Impact factor: 7.344

8.  Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.

Authors:  Emily C Gale; Abigail E Powell; Gillie A Roth; Emily L Meany; Jerry Yan; Ben S Ou; Abigail K Grosskopf; Julia Adamska; Vittoria C T M Picece; Andrea I d'Aquino; Bali Pulendran; Peter S Kim; Eric A Appel
Journal:  Adv Mater       Date:  2021-10-14       Impact factor: 32.086

9.  Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection.

Authors:  Alvaro Baeza Garcia; Edwin Siu; Tiffany Sun; Valerie Exler; Luis Brito; Armin Hekele; Gib Otten; Kevin Augustijn; Chris J Janse; Jeffrey B Ulmer; Jürgen Bernhagen; Erol Fikrig; Andrew Geall; Richard Bucala
Journal:  Nat Commun       Date:  2018-07-13       Impact factor: 14.919

10.  Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults.

Authors:  Said A Jongo; Vicente Urbano; L W Preston Church; Ally Olotu; Stephen R Manock; Tobias Schindler; Ali Mtoro; Natasha Kc; Ali Hamad; Elizabeth Nyakarungu; Maximillian Mpina; Anna Deal; José Raso Bijeri; Martin Eka Ondo Mangue; Beltrán Ekua Ntutumu Pasialo; Genaro Nsue Nguema; Salomon Nguema Owono; Matilde Riloha Rivas; Mwajuma Chemba; Kamaka R Kassim; Eric R James; Thomas C Stabler; Yonas Abebe; Elizabeth Saverino; Julian Sax; Salome Hosch; Anneth-Mwasi Tumbo; Linda Gondwe; J Luis Segura; Carlos Cortes Falla; Wonder Philip Phiri; Dianna E B Hergott; Guillermo A García; Christopher Schwabe; Carl D Maas; Tooba Murshedkar; Peter F Billingsley; Marcel Tanner; Mitoha Ondo'o Ayekaba; B Kim Lee Sim; Claudia Daubenberger; Thomas L Richie; Salim Abdulla; Stephen L Hoffman
Journal:  Am J Trop Med Hyg       Date:  2021-01       Impact factor: 2.345

View more
  1 in total

Review 1.  RTS,S/AS01 malaria vaccine (Mosquirix®): a profile of its use.

Authors:  Yahiya Y Syed
Journal:  Drugs Ther Perspect       Date:  2022-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.